CO2021017960A2 - Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 - Google Patents

Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1

Info

Publication number
CO2021017960A2
CO2021017960A2 CONC2021/0017960A CO2021017960A CO2021017960A2 CO 2021017960 A2 CO2021017960 A2 CO 2021017960A2 CO 2021017960 A CO2021017960 A CO 2021017960A CO 2021017960 A2 CO2021017960 A2 CO 2021017960A2
Authority
CO
Colombia
Prior art keywords
glp
glucagon
agonists
peptide
pharmaceutical compositions
Prior art date
Application number
CONC2021/0017960A
Other languages
English (en)
Inventor
Dos Santos Ana Lucia Gomes
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CO2021017960A2 publication Critical patent/CO2021017960A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona formulaciones para administración parenteral de péptidos agonistas de GLP-1/glucagón, métodos para producir dichas formulaciones y métodos de tratamiento usando dichas formulaciones.
CONC2021/0017960A 2019-07-01 2021-12-28 Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 CO2021017960A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869263P 2019-07-01 2019-07-01
PCT/EP2020/068411 WO2021001374A1 (en) 2019-07-01 2020-06-30 Pharmaceutical compositions for glucagon and glp-1 co-agonist peptides

Publications (1)

Publication Number Publication Date
CO2021017960A2 true CO2021017960A2 (es) 2022-01-17

Family

ID=71575348

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017960A CO2021017960A2 (es) 2019-07-01 2021-12-28 Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1

Country Status (19)

Country Link
US (1) US20230159606A1 (es)
EP (1) EP3993823A1 (es)
JP (1) JP2022539200A (es)
KR (1) KR20220027204A (es)
CN (1) CN114126639A (es)
AR (1) AR119324A1 (es)
AU (1) AU2020299978A1 (es)
BR (1) BR112021026575A2 (es)
CA (1) CA3144177A1 (es)
CL (1) CL2021003497A1 (es)
CO (1) CO2021017960A2 (es)
CR (1) CR20220046A (es)
EA (1) EA202290107A1 (es)
IL (1) IL289437A (es)
MA (1) MA56448A (es)
MX (1) MX2021015930A (es)
PE (1) PE20220513A1 (es)
TW (1) TW202116814A (es)
WO (1) WO2021001374A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
JP7237590B6 (ja) 2016-03-10 2023-03-28 メドイミューン・リミテッド 肥満の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト

Also Published As

Publication number Publication date
BR112021026575A2 (pt) 2022-04-26
EA202290107A1 (ru) 2022-03-29
CL2021003497A1 (es) 2022-09-30
AU2020299978A1 (en) 2022-02-24
JP2022539200A (ja) 2022-09-07
MA56448A (fr) 2022-05-11
AR119324A1 (es) 2021-12-09
WO2021001374A1 (en) 2021-01-07
IL289437A (en) 2022-02-01
KR20220027204A (ko) 2022-03-07
TW202116814A (zh) 2021-05-01
CA3144177A1 (en) 2021-01-07
MX2021015930A (es) 2022-02-03
CN114126639A (zh) 2022-03-01
PE20220513A1 (es) 2022-04-07
EP3993823A1 (en) 2022-05-11
CR20220046A (es) 2022-03-24
US20230159606A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
PH12020550051A1 (en) Glp-1 compositions and uses thereof
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
BR112016026811A2 (pt) formulação de anticorpo
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
AR095386A1 (es) Péptidos de kntc2 y vacunas que los contienen
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
CO2021017960A2 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
EA201992142A1 (ru) Фармацевтические композиции и их применения
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.